Income Statement (TTM)
VISEN Pharmaceuticals Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2022 12-31 |
2023 12-31 |
2024 09-30 |
2024 12-31 |
|
|---|---|---|---|---|
| Revenue | -2 | -2 | 111 | 3 |
| Change (%) | -27.37 | -6,775.43 | -97.51 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | ||||
| Change (%) | ||||
| % of Revenue | ||||
| Gross Operating Profit | -2 | -2 | 111 | 3 |
| Change (%) | -27.37 | -6,775.43 | -97.51 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 |
| SG&A | 177 | 80 | 80 | 86 |
| Change (%) | -54.95 | 0.40 | 7.68 | |
| % of Revenue | -7,721.89 | -4,789.93 | 72.04 | 3,112.50 |
| R&D | 180 | 58 | 79 | 91 |
| Change (%) | -67.87 | 36.10 | 15.29 | |
| % of Revenue | -7,813.14 | -3,456.56 | 70.47 | 3,259.67 |
| OpEx | 357 | 138 | 159 | 177 |
| Change (%) | -61.45 | 15.36 | 11.45 | |
| % of Revenue | -15,535.03 | -8,246.49 | 142.51 | 6,372.16 |
| Operating Income | -359 | -139 | -47 | -174 |
| Change (%) | -61.23 | -66.00 | 267.72 | |
| % of Revenue | 15,635.03 | 8,346.49 | -42.51 | -6,272.16 |
| Interest Expense | -1 | -0 | -0 | -0 |
| Change (%) | -48.79 | -37.54 | -18.69 | |
| % of Revenue | 26.94 | 18.99 | -0.18 | -5.80 |
| Net Income | -289 | -250 | -171 | -182 |
| Change (%) | -13.63 | -31.59 | 6.75 | |
| % of Revenue | 12,574.72 | 14,953.27 | -153.23 | -6,562.55 |
Source: Capital IQ
